ORKA Oruka Therapeutics, Inc.
Price Chart
Executive Summary
Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded warrants, with an additional $75M option for underwriters. The proceeds will support its clinical-stage pipeline for psoriasis and inflammatory diseases. The offering represents roughly 15% dilution at current market cap, which is a negative signal for near-term stock price.
Key Financial Metrics
Actionable Insight
Expect near-term price weakness due to dilution. Watch for pricing details in the prospectus supplement and any updates on use of proceeds. The stock may find support if proceeds are allocated to promising pipeline catalysts.
Key Facts
- $500M underwritten public offering of common stock and pre-funded warrants
- Underwriters have a 30-day option to purchase up to an additional $75M of shares
- Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities are joint bookrunning managers
- Shelf registration statement (Form S-3) became effective on April 10, 2026
- Offering size is approximately 14.7% of the $3.4B market cap
Financial Impact
Approximately $500M raised (up to $575M with greenshoe), diluting existing shareholders by ~14.7% at current market cap
Risk Factors
- Dilution of existing shareholders
- Offering may not close if market conditions deteriorate
- Clinical-stage biotech carries inherent pipeline risk
- Potential for further offerings as cash needs increase
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
8d ago
|
8-K
| $55.23 $57.20 | ▲ +3.57% | ▲ +4.26% | $64.06 (+15.99%) |
|
May 22, 2026
18d ago
|
Insider Cluster
| $59.06 $57.99 | ▼ −1.81% | ▼ −1.82% | $64.06 (+8.47%) |
|
May 18, 2026
22d ago
|
Insider Cluster
| $57.50 $60.67 | ▲ +5.51% | ▲ +4.47% | $64.06 (+11.41%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $68.10 $68.10 | · 0.00% | ▲ +1.02% | $64.06 (+5.93%) |
|
Apr 27, 2026
6w ago
|
424B5
| $73.99 $69.49 | ▲ +6.08% | ▲ +6.07% | $64.06 (+13.42%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $73.99 $69.49 | ▲ +6.08% | ▲ +6.07% | $64.06 (+13.42%) |
|
Apr 27, 2026
6w ago
|
8-K
| $76.39 $73.99 | ▼ −3.14% | ▼ −2.66% | $64.06 (−16.14%) |
|
Apr 17, 2026
7w ago
|
DEFA14A
| $68.87 $69.00 | ▲ +0.19% | ▲ +0.84% | $64.06 (−6.98%) |
|
Apr 15, 2026
7w ago
|
144
| $67.07 $68.92 | ▲ +2.76% | ▲ +1.54% | $64.06 (−4.49%) |
|
Apr 13, 2026
8w ago
|
EFFECT
| $61.38 $67.06 | ▲ +9.25% | ▲ +8.04% | $64.06 (+4.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access